Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2011 Dec 8;21(7):697–709. doi: 10.1002/pds.2256

TABLE 1.

Explanation of simulation parameters and other symbols.

Parameter Explanation Range of values
X Dichotomous exposure 0 or 1
Y Count outcome ≥0
Ci Ten dichotomous confounders 0 or 1
P(Ci) Prevalence of confounder i 5% to 25% in increments of 5%
β0 Baseline exposure prevalence 25% or 50%
βCi Strength of the confounder-exposure association log(1.5) to log(4.0) in increments of 0.5
βPS−INT Strength of the C1 by C2 within-PS interaction log(1.0)
log(3.0) to log(5.0) in increments of 0.5
γX Treatment effect log(1.0) to log(5.0) in increments of 1.0
γ0 Baseline outcome rate 0.01, 0.10, 0.25 or 0.50 events per unit of person-time
γCi Strength of the confounder-outcome association log(1.5) to log(4.0) in increments of 0.5
γTX−INT Strength of the C1 by treatment interaction log(1.0)
log(3.0) to log(5.0) in increments of 0.5
PSCOH Propensity score estimated in the entire cohort 0 to 1
PSSS Propensity score estimated in the subgroup 0 to 1
a Number of exposed outcomes in the entire cohort As observed
aC1=1 Number of exposed outcomes in the subgroup of C1 =1 As observed